RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+4.99%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$707M
AUM Growth
+$707M
(+26%)
Cap. Flow
+$106M
Cap. Flow
% of AUM
15.03%
Top 10 Holdings %
Top 10 Hldgs %
27.95%
Holding
103
New
12
Increased
42
Reduced
34
Closed
6
Top Buys
| 1 |
Johnson & Johnson
JNJ
|
$18.6M |
| 2 |
UnitedHealth
UNH
|
$12.3M |
| 3 |
Cooper Companies
COO
|
$7.3M |
| 4 |
ESRX
Express Scripts Holding Company
ESRX
|
$7.03M |
| 5 |
Medtronic
MDT
|
$6.36M |
Top Sells
| 1 |
Lexicon Pharmaceuticals
LXRX
|
$11.5M |
| 2 |
Amgen
AMGN
|
$4.61M |
| 3 |
OCR
OMNICARE INC
OCR
|
$3.85M |
| 4 |
Gilead Sciences
GILD
|
$3.4M |
| 5 |
Universal Health Services
UHS
|
$3.13M |
Sector Composition
| 1 | Healthcare | 90.66% |
| 2 | Financials | 0.92% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
UnitedHealth
UNH
$281B
| $28.2M | 3.38% | 231,000 +101,000 | +78% | +$12.3M |
|
|
ALXN
2
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $24M | 2.88% | 132,800 +17,822 | +16% | +$3.22M |
|
3
Alkermes
ALKS
$4.78B
| $22.5M | 2.7% | 349,000 +91,000 | +35% | +$5.86M |
|
4
Biogen
BIIB
$19.4B
| $20.3M | 2.44% | 50,291 +9,591 | +24% | +$3.87M |
|
5
CVS Health
CVS
$92.8B
| $19.3M | 2.32% | 184,000 +39,000 | +27% | +$4.09M |
|
|
6
Johnson & Johnson
JNJ
$427B
| $18.6M | 2.24% | +191,000 | New | +$18.6M |
|
7
Cardinal Health
CAH
$35.5B
| $18M | 2.16% | 215,000 +73,600 | +52% | +$6.16M |
|
|
CELG
8
DELISTED
Celgene Corp
CELG
| $15.9M | 1.9% | 137,000 -14,000 | -9% | -$1.62M |
|
9
AbbVie
ABBV
$372B
| $15.7M | 1.88% | 233,000 +13,000 | +6% | +$873K |
|
|
10
Gilead Sciences
GILD
$140B
| $15.2M | 1.83% | 130,000 -29,000 | -18% | -$3.4M |
|
|
RAD
11
DELISTED
Rite Aid Corporation
RAD
| $15.2M | 1.82% | 1,817,000 +540,538 | +42% | +$4.51M |
|
12
Merck
MRK
$210B
| $14.8M | 1.78% | 260,000 -40,000 | -13% | -$2.28M |
|
13
Eli Lilly
LLY
$657B
| $14.6M | 1.75% | 175,000 +46,000 | +36% | +$3.84M |
|
14
Bristol-Myers Squibb
BMY
$96B
| $13.2M | 1.58% | 198,000 +69,000 | +53% | +$4.59M |
|
|
AGN
15
DELISTED
Allergan plc
AGN
| $12.7M | 1.53% | 42,000 -3,300 | -7% | -$1M |
|
16
BioMarin Pharmaceuticals
BMRN
$11.2B
| $12.6M | 1.51% | 92,000 +17,000 | +23% | +$2.33M |
|
17
Jazz Pharmaceuticals
JAZZ
$7.75B
| $12.3M | 1.48% | 70,000 +15,000 | +27% | +$2.64M |
|
18
Nektar Therapeutics
NKTR
$568M
| $11.7M | 1.41% | 937,000 -59,600 | -6% | -$746K |
|
|
19
Medtronic
MDT
$119B
| $11.5M | 1.38% | 154,800 +85,800 | +124% | +$6.36M |
|
20
Incyte
INCY
$16.5B
| $11.2M | 1.35% | 107,502 -12,498 | -10% | -$1.3M |
|
|
21
Amgen
AMGN
$155B
| $10.6M | 1.27% | 69,000 -30,000 | -30% | -$4.61M |
|
22
Regeneron Pharmaceuticals
REGN
$61.5B
| $9.69M | 1.16% | 19,000 -3,000 | -14% | -$1.53M |
|
|
CEMP
23
DELISTED
Cempra, Inc.
CEMP
| $9.52M | 1.14% | 277,161 +91,861 | +50% | +$3.16M |
|
24
Elevance Health
ELV
$71.8B
| $9.52M | 1.14% | 58,000 +1,000 | +2% | +$164K |
|
|
25
Universal Health Services
UHS
$11.6B
| $9.24M | 1.11% | 65,000 -22,000 | -25% | -$3.13M |
|